EUCTR2022-003595-16-IT招募中1 期
Phase 2, open-label, single-arm study on the use of metformin as adjunctive therapy in high-grade glioma - GBM-MET
IVERSITÀ DEGLI STUDI MILANO BICOCCA0 个研究点目标入组 25 人开始时间: 2023年1月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Patients with newly diagnosed histologically confirmed GBM (WHO grade IV, IDH wild type) undergoing surgical resection;
- •- Hypomethylation or hypermethylation of MGMT evaluated post-surgery;
- •- Adult patients (=18 years), both sexes;
- •- Patients undergoing Stupp protocol including patients aged >70 years performing hypofractionated protocol and three weeks of chemotherapy;
- •- Karnofsky Performance Status (KPS) > 60 assessed post-surgery;
- •- Life expectancy at least 6 months defined by tumor lesion size and location;
- •- Freely given written informed consent prior to any study-related activity. Patients must be able to communicate with the investigator and comply with study procedures;
- •- Women of childbearing age must test negative for pregnancy at enrollment and, if they have sex, must agree to use specific contraceptive methods. Female subjects of childbearing age, i.e., fertile, after menarche and until post-menopause unless permanently infertile, who are sexually active, must apply a highly effective method of birth control with a low failure rate (i.e., less than 1 percent per year), such as combined hormonal contraception (containing estrogen and progestin) combined with ovulation inhibition (oral intravaginal, or transdermal), progestin-only hormonal contraception associated with ovulation inhibition (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormone delivery system (IUS), bilateral tubal occlusion, vasectomized partner, or sexual abstinence, throughout the treatment period and for four weeks after the last dose of the study treatment. Hormonal methods other than levonorgestrel-containing devices or medroxyprogesterone injections should be supplemented with the use of a male condom. Women of nonfertile age may be included if surgically sterile or postmenopausal for at least 2 years. The investigator is responsible for determining whether the patient has adopted an appropriate method of contraception for participation in the study.
- •- Male subjects with female partners of childbearing age must use condoms during treatment and until the end of relevant systemic exposure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Multicenter GBMs;
- •- Patients diagnosed with diabetes or diabetes-related conditions;
- •- Other active malignancies;
- •- Hypersensitivity, intolerance to metformin or excipients;
- •- Impaired renal function with creatinine clearance < 60 mL/min assessed at recruitment; liver failure assessed at recruitment by clinical history and examination of ALT, AST and total bilirubin; and other contraindications to metformin use;
- •- Taking metformin, insulin or other biguanides, regardless of the reason;
- •- Pregnancy or lactation;
- •- The patient has serious pre-existing medical conditions that, in the opinion of the investigator, would preclude participation in this study.
研究者
相似试验
进行中（未招募）
1 期
A study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of chemotherapy with paclitaxel in patients with unresectable locally advanced or metastatic breast cancer with aggressive disease criteria.EUCTR2020-001648-24-PTMedica Scientia Innovation Research (MEDSIR)160
进行中（未招募）
1 期
A study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant)with or without a short course of chemotherapy with paclitaxel in patients withunresectable locally advanced or metastatic breast cancer with aggressive disease criteria.Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease criteria.MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2020-001648-24-ITMEDICA SCIENTIA INNOVATION RESEARCH S.L.160
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
进行中（未招募）
1 期
Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARPeoadjuvant TNBCMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2010-018960-17-DEsanofi-aventis recherche & développement
进行中（未招募）
1 期
Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARPeoadjuvant TNBCMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2010-018960-17-FRsanofi-aventis recherche & développement